Aptar Sees FY26 Capital Expenditures of $260M-$280M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Should l Buy ATR?
Sees Q1 effective tax rate 21%-23%. Sees FY26 capital expenditures $260M-$280M. . Regarding Aptar's outlook, Tanda stated, "Looking ahead to the first quarter and 2026, we expect strong growth within Pharma outside of emergency medicine, which is going through a period of destocking. Injectables, systemic nasal drug delivery and our consumer healthcare solutions are expected to deliver continued growth. In Beauty, we are seeing early signs of strengthening demand in prestige fragrance, and Closures is expected to deliver steady performance as innovation and category conversion continue to lead the way. We believe that our determination to drive further productivity gains, combined with a strong balance sheet, provides the ability to return capital to shareholders while retaining strategic flexibility and continuing to invest in the business for long-term value creation."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is 148.00 USD with a low forecast of 133.00 USD and a high forecast of 172.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 123.980
Low
133.00
Averages
148.00
High
172.00
Current: 123.980
Low
133.00
Averages
148.00
High
172.00
About ATR
AptarGroup, Inc. is engaged in designing and manufacturing of drug and consumer product dosing, dispensing and protection technologies. The Company serves various end markets, including pharmaceutical, beauty, food, beverage, personal care and home care. It operates in three segments. The Aptar Pharma segment sells proprietary dispensing systems, drug delivery systems, sealing solutions and services for the prescription drug, consumer health care, injectables, active material science solutions and digital health market. It also specializes in nasal drug delivery for delivering drugs. The Aptar Beauty segment sells dispensing systems and sealing solutions for the beauty, personal care and home care markets. The Aptar Closures segment sells dispensing systems, sealing solutions and food service trays to the food, beverage, personal care, home care, beauty and healthcare markets. This segment also includes the food protection business and the elastomeric flow-control technology business.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AptarGroup Reports Strong Q4 2025 Earnings with Strategic Insights
- Significant Sales Growth: AptarGroup reported Q4 sales of $963 million, reflecting a 14% year-over-year increase, with core sales up 5%, indicating strong performance across all business segments, particularly in Pharma where demand is rebounding.
- Margin Pressures: Adjusted EBITDA was $191 million with a margin of 19.8%, down from the previous year, primarily due to rising production costs and shifts in product mix, highlighting challenges in cost management for the company.
- Shareholder Return Strategy: In 2025, AptarGroup returned $486 million to shareholders through buybacks and dividends, demonstrating a commitment to shareholder value, while capital expenditures represented 7% of sales, indicating a focus on high-return investments.
- Future Outlook: Management anticipates a $65 million revenue headwind from emergency medicine in 2026; nevertheless, the company remains committed to achieving a long-term core sales growth target of 7% to 11% and plans to continue capital investments and stock buybacks in the future.
See More
AptarGroup Reports Decline in Q4 Profit
- Profit Decline: AptarGroup's Q4 net profit fell to $74.34 million, or $1.13 per share, representing a 24% decrease from last year's $1.49 per share, indicating significant challenges in profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $82.06 million, or $1.25 per share, which, while relatively stable, could not offset the overall decline in net profit.
- Revenue Growth: The company's revenue increased by 13.5% year-over-year to $962.73 million, up from $848 million last year, demonstrating strong market demand and growth in product sales.
- Future Guidance: AptarGroup's EPS guidance for the next quarter is set between $1.13 and $1.21, suggesting that despite the current profit decline, the company maintains a cautiously optimistic outlook on future profitability, reflecting management's confidence in market recovery.
See More
AptarGroup Q4 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q4 Non-GAAP EPS of $1.25, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Significant Revenue Growth: The company achieved Q4 revenues of $963 million, a 13.5% year-over-year increase, surpassing analyst expectations by $84.42 million, reflecting strong market demand recovery.
- Strong Market Performance: The quarterly growth was driven by successful expansions in multiple markets, particularly in the packaging solutions sector, further solidifying its market leadership.
- Optimistic Future Outlook: AptarGroup's robust earnings report lays a foundation for future investments and expansions, with expectations to benefit from changing global consumer trends and the launch of innovative products.
See More
AptarGroup to Announce Q4 Earnings on February 5th
- Earnings Announcement Schedule: AptarGroup (ATR) is set to release its Q4 earnings on February 5th after market close, with consensus EPS estimate at $1.23, reflecting a 17.4% year-over-year decline, while revenue is projected at $878.58 million, indicating a 3.6% year-over-year growth, showcasing potential for revenue growth.
- Historical Performance Review: Over the past two years, AptarGroup has beaten EPS estimates 75% of the time, although it has only surpassed revenue estimates 38% of the time, indicating relative stability in profitability but challenges in revenue growth.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and six downward revisions, with revenue estimates also facing six downward adjustments, reflecting a cautious market outlook on the company's future performance, which may impact investor confidence.
- Industry Conference Participation: AptarGroup will also present at the 44th Annual J.P. Morgan Healthcare Conference and at the Jefferies London Healthcare Conference in 2025, indicating the company's proactive engagement in industry discussions to enhance market presence and attract investor attention.
See More
Aptar Achieves Prestigious 'A' Score on CDP Climate Change Assessment for Second Year
- Climate Leadership: Aptar has secured an 'A' score from CDP for the second consecutive year, reflecting its ongoing commitment to emission reductions and climate risk management, thereby reinforcing its leadership in drug delivery and consumer products.
- Emission Reduction Targets: The company has established science-based targets aimed at limiting greenhouse gas emissions to align with the 1.5°C goal by 2030, demonstrating a strong commitment to sustainability supported by renewable energy purchase agreements.
- Transparency and Accountability: Aptar's improvements in climate-related financial disclosures, in line with TCFD requirements, enhance its transparency and accountability in the global market, which is crucial for attracting investor interest in its sustainability initiatives.
- Industry Impact: With over 22,000 companies disclosing environmental data through CDP in 2025, Aptar ranks in the top 4%, which not only boosts its brand image but also provides substantial support for its competitive position in the global market.
See More
AptarGroup Supports CastleVax's Phase II Clinical Trial of COVID-19 Vaccine with Innovative Delivery Solutions
- Vaccine Delivery Innovation: AptarGroup's LuerVax® and Spray Divider™ are utilized in CastleVax's Phase II clinical trial of CVAX-01, underscoring the company's ongoing commitment to advancing vaccine delivery technologies, which is expected to enhance the effectiveness and convenience of vaccination.
- Clinical Trial Scale: The trial will follow approximately 200 U.S. adults, including high-risk individuals and those over 65, for six months to assess the safety and immune response of the nasal vaccine, potentially providing critical data for future vaccine development.
- Technical Support Advantage: By offering comprehensive regulatory guidance and technical support, Aptar helps customers navigate complexities, thereby accelerating the delivery of life-changing therapies, further solidifying its leadership in nasal vaccine delivery systems.
- Market Impact: Aptar's expertise and innovative design capabilities position it as the preferred partner for pharmaceutical collaborators, driving the development of next-generation medicines and significantly enhancing the company's competitiveness in the global drug delivery market.
See More
AptarGroup Reports Strong Q4 2025 Earnings with Strategic Insights
- Significant Sales Growth: AptarGroup reported Q4 sales of $963 million, reflecting a 14% year-over-year increase, with core sales up 5%, indicating strong performance across all business segments, particularly in Pharma where demand is rebounding.
- Margin Pressures: Adjusted EBITDA was $191 million with a margin of 19.8%, down from the previous year, primarily due to rising production costs and shifts in product mix, highlighting challenges in cost management for the company.
- Shareholder Return Strategy: In 2025, AptarGroup returned $486 million to shareholders through buybacks and dividends, demonstrating a commitment to shareholder value, while capital expenditures represented 7% of sales, indicating a focus on high-return investments.
- Future Outlook: Management anticipates a $65 million revenue headwind from emergency medicine in 2026; nevertheless, the company remains committed to achieving a long-term core sales growth target of 7% to 11% and plans to continue capital investments and stock buybacks in the future.
See More
AptarGroup Reports Decline in Q4 Profit
- Profit Decline: AptarGroup's Q4 net profit fell to $74.34 million, or $1.13 per share, representing a 24% decrease from last year's $1.49 per share, indicating significant challenges in profitability.
- Adjusted Earnings: Excluding items, the company reported adjusted earnings of $82.06 million, or $1.25 per share, which, while relatively stable, could not offset the overall decline in net profit.
- Revenue Growth: The company's revenue increased by 13.5% year-over-year to $962.73 million, up from $848 million last year, demonstrating strong market demand and growth in product sales.
- Future Guidance: AptarGroup's EPS guidance for the next quarter is set between $1.13 and $1.21, suggesting that despite the current profit decline, the company maintains a cautiously optimistic outlook on future profitability, reflecting management's confidence in market recovery.
See More
AptarGroup Q4 Earnings Exceed Expectations
- Earnings Beat: AptarGroup reported a Q4 Non-GAAP EPS of $1.25, exceeding expectations by $0.02, indicating the company's stable profitability and growth potential.
- Significant Revenue Growth: The company achieved Q4 revenues of $963 million, a 13.5% year-over-year increase, surpassing analyst expectations by $84.42 million, reflecting strong market demand recovery.
- Strong Market Performance: The quarterly growth was driven by successful expansions in multiple markets, particularly in the packaging solutions sector, further solidifying its market leadership.
- Optimistic Future Outlook: AptarGroup's robust earnings report lays a foundation for future investments and expansions, with expectations to benefit from changing global consumer trends and the launch of innovative products.
See More
AptarGroup to Announce Q4 Earnings on February 5th
- Earnings Announcement Schedule: AptarGroup (ATR) is set to release its Q4 earnings on February 5th after market close, with consensus EPS estimate at $1.23, reflecting a 17.4% year-over-year decline, while revenue is projected at $878.58 million, indicating a 3.6% year-over-year growth, showcasing potential for revenue growth.
- Historical Performance Review: Over the past two years, AptarGroup has beaten EPS estimates 75% of the time, although it has only surpassed revenue estimates 38% of the time, indicating relative stability in profitability but challenges in revenue growth.
- Expectation Revisions: In the last three months, there have been no upward revisions for EPS estimates and six downward revisions, with revenue estimates also facing six downward adjustments, reflecting a cautious market outlook on the company's future performance, which may impact investor confidence.
- Industry Conference Participation: AptarGroup will also present at the 44th Annual J.P. Morgan Healthcare Conference and at the Jefferies London Healthcare Conference in 2025, indicating the company's proactive engagement in industry discussions to enhance market presence and attract investor attention.
See More
Aptar Achieves Prestigious 'A' Score on CDP Climate Change Assessment for Second Year
- Climate Leadership: Aptar has secured an 'A' score from CDP for the second consecutive year, reflecting its ongoing commitment to emission reductions and climate risk management, thereby reinforcing its leadership in drug delivery and consumer products.
- Emission Reduction Targets: The company has established science-based targets aimed at limiting greenhouse gas emissions to align with the 1.5°C goal by 2030, demonstrating a strong commitment to sustainability supported by renewable energy purchase agreements.
- Transparency and Accountability: Aptar's improvements in climate-related financial disclosures, in line with TCFD requirements, enhance its transparency and accountability in the global market, which is crucial for attracting investor interest in its sustainability initiatives.
- Industry Impact: With over 22,000 companies disclosing environmental data through CDP in 2025, Aptar ranks in the top 4%, which not only boosts its brand image but also provides substantial support for its competitive position in the global market.
See More
AptarGroup Supports CastleVax's Phase II Clinical Trial of COVID-19 Vaccine with Innovative Delivery Solutions
- Vaccine Delivery Innovation: AptarGroup's LuerVax® and Spray Divider™ are utilized in CastleVax's Phase II clinical trial of CVAX-01, underscoring the company's ongoing commitment to advancing vaccine delivery technologies, which is expected to enhance the effectiveness and convenience of vaccination.
- Clinical Trial Scale: The trial will follow approximately 200 U.S. adults, including high-risk individuals and those over 65, for six months to assess the safety and immune response of the nasal vaccine, potentially providing critical data for future vaccine development.
- Technical Support Advantage: By offering comprehensive regulatory guidance and technical support, Aptar helps customers navigate complexities, thereby accelerating the delivery of life-changing therapies, further solidifying its leadership in nasal vaccine delivery systems.
- Market Impact: Aptar's expertise and innovative design capabilities position it as the preferred partner for pharmaceutical collaborators, driving the development of next-generation medicines and significantly enhancing the company's competitiveness in the global drug delivery market.
See More
